[1] World Health Organization. Global tuberculosis report(2019) [EB/OL]. (2019-10-17)[2019-11-28]. https://www.who.int/tb/publications/global_report/en/. [2] Chellini PR, Lages EB, Franco PHC, et al.Development and validation of an HPLC method for simultaneous determination of rifampicin, isoniazid, pyrazinamide, and ethambutol hydrochloride in pharmaceutical formulations[J]. Journal of AOAC International, 2015, 98(5): 1234-1239. [3] Shenyang Hongqi Pharmaceutical Co.Ltd.. The instruction of the ethambutol hydrochloride, pyrazinamide, ifampicin and isoniazid tablets(Ⅱ)[EB/OL].(2007-01-18)[2019-11-28].http://www.hongqipharma.com/products_detail/productId=105.html. [4] Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, et al. Guideline for primary care of pulmonary tuberculosis:practice version(2018)[J].Chin J Gen Pract(中华全科医师杂志), 2019, 18(8): 718-722. [5] Li J, Luo MF.Analysis of serious delayed rash caused by ethambutol hydrochloride, pyrazinamide, rifampicin and isoniazid tablets[J]. Drug Evaluation(药品评价), 2017, 14(4): 59-61. [6] Wang KM.Efficacy analysis of adverse reactions caused by ethambutol hydrochloride, pyrazinamide, rifampicin and isoniazid tablets(Ⅱ) in the treatment of pulmonary tuberculosis[J]. Medical Community, 2018(24): 89. [7] Xiao ZY, Qian HF.Analysis of 106 ADR/ADE induced by ethambutol hydrochloride, pyrazinamide, rifampicin and isoniazid Tablets(Ⅱ) in the treatment of pulmonary tuberculosis[J]. China Pharmacy(中国药房), 2014, 25(24): 2286-2288. [8] Zimmerli W, Trampuz A, Ochsner PE.Prosthetic-joint infections[J]. N Engl J Med, 2004, 351: 1645-1654. [9] Brockhaus L, Schmid Y, Rast AC, et al.Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports[J]. BMC Pharmacol Toxicol, 2019, 20(1): 9-15. [10] Sakashita K, Murata K, Takahashi Y, et al.A case series of acute kidney injury during anti-tuberculosis treatment[J].Internal Medicine, 2019, 58(4): 521-527. [11] Pereira A, Sanz C, Cervantes F, et al.Immune hemolytic anemia and renal failure associated with rifampicin-dependent antibodies with anti-I specificity[J]. Ann Hematol, 1991, 63(1): 56-58. [12] Du CH, Zhao YL, Zhao QG.A case of antituberculosis drugs-associated acute multi-organic functional damage[J]. Evaluation and Analysis of Drug-use in Hospitals of China(中国医院用药评价与分析), 2017, 17(9): 1171-1175. [13] Cao Z, Guo L, Niu K, et al.Clinical analysis of acute renal failure caused by rifampicin[J]. Chinese Journal of Integrated Traditional and Western Nephrology(中国中西医结合肾病杂志), 2005(2): 102-103. [14] Li YL, Zhang HF, Dai HM, et al.Diagnosis and treatment of drug-induced renal injury combined with acute renal failure[J]. Jilin Medical Journal(吉林医学), 2008, 29(17): 1456-1457. [15] Li SJ, He JG.A case report of acute renal failure caused by pyrazin-amide[J]. Journal of New Medicine(新医学), 2005, 36(11): 665-666. [16] Cui R, Wei W, Bu YS.Research progress on markers of renal damage in the diagnosis of drug-induced renal injury[J]. Tianjin Pharmacy(天津药学), 2017, 29(4): 62-65. [17] Zhi YP.The biomarkers for acute kidney injury: a clear road ahead[J]. Journal of Translational Internal Medicine, 2016, 4(3): 95-98. [18] Yoshihiro K, Takahiro A, Eriko S, et al.Desensitization therapy for allergic reactions to antituberculous drugs[J]. Intern Med, 2010, 49(21): 2297-2301. |